George Mason University's Yuntao Wu is the lead scientist on a research team that has identified a measurable indicator that could prove instrumental in the fight against HIV.
The research focuses on cofilin, a key protein that regulates cells to mobilize and fight against infection.
In an HIV-infected patient, cofilin dysfunction is a key factor in helper T cell defects, according to the research recently published in the journal Science Advances. Helper T cells augment the body's immune response by recognizing the presence of a foreign antigen and then helping the immune system mount a response.
"When you have an infection, you need to mobilize the T cells," said Wu, a College of Science professor of molecular and microbiology within Mason's School of Systems Biology and National Center for Biodefense and Infectious Diseases. "In HIV infection, there is a profound depletion of helper T cells in lymphoid tissues, such as those in the gut."
Antiretroviral therapy has significantly increased the lifespan of HIV-infected people, although it offers neither a cure nor a full restoration of the body's immune system, he said. The natural course of the HIV infection leads to multiple immune defects, including the impairment of T cell migration, according to the research team.
Wu and his team found that patients with HIV have "significantly lower" levels of cofilin phosphorylation--which provides a control of cofilin's activity with the addition of a phosphate--than healthy patients. Cofilin is a key protein that helps cells generate the driving force for migration. Proper cofilin phosphorylation is needed for cells to move in and out of tissues.
Their findings suggest that a lasting immune control to HIV isn't likely to come from antiretroviral therapy alone because it is not sufficient to repair the cofilin damage caused by HIV and to restore normal T cell migration in and out of tissues.
But the researchers found that by stimulating the T cells with additional therapeutics, such as the α4β7 integrin antibody, they could modulate the levels of cofilin activity needed to restore T cell mobility. The remedy has shown lasting effects in immune control of simian immunodeficiency virus (SIV), the simian form of the AIDS virus, in a monkey trial, but it has not showed the same results in HIV-infected human patients.
"Now we have a marker, and at least one target that we can focus on to discover new therapies to repair the immune damages for a functional cure," Wu said.
Source: George Mason University
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
Robust infectious disease surveillance, including rapid subtyping of influenza A, is essential for early detection, containment, and public health reporting of novel viral threats.